Skip to main content
Fig. 4 | Journal of Ovarian Research

Fig. 4

From: Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer

Fig. 4

CRAd progeny amplification in OvCa cells. The titers of infectious viral progeny produced in OvCa cell lines were determined using the Viral ToxGlo assay (Promega) to measure cellular ATP level, as surrogate of cell viability. Monolayers of A549 cells were infected with serial dilutions of lysates of the indicated OvCa cells, which were infected with CRAd-ING4, CRAd-IL24, or control CRAd to determine a cytotoxic endpoint effect (50 % CPE or tissue culture infective dose TCID50) 6 days postinfection. Each data point represents the cumulative mean ± SD (error bars are smaller than the symbols, p ≤ 0.05)

Back to article page